BofA on Catalyst Pharmaceutical (CPRX): 'Firdapse IP settlement sets favorable LOE, assuming other 2 generic filers follow suit'
Tweet Send to a Friend
BofA Securities analyst Jason M. Gerberry reiterated a Buy rating and $30.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
